A Look At Surgery Partners (SGRY) Valuation After Softer Results And Rising Debt Concerns
Surgery Partners (SGRY) is facing investor caution due to weaker quarterly results, including soft sales, slower projected revenue growth, and high debt. Despite a significant share price decline, analysts still see the stock as undervalued, with a fair value of around $25.45 compared to its current $12.18, contingent on effective M&A and portfolio optimization. However, rising interest costs and slower acquisitions present risks to this valuation narrative.
Surgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of "Moderate Buy" by Analysts
Surgery Partners, Inc. (NASDAQ:SGRY) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $23.36. Despite missing EPS expectations with $0.12 reported versus an estimated $0.31, the company's revenue beat at $885M, and its board authorized a $200 million share buyback program. Insider sales totaling approximately $1.28 million have occurred over the last 90 days, including transactions by the CEO.
SG Americas Securities LLC Purchases 549,945 Shares of Surgery Partners, Inc. $SGRY
SG Americas Securities LLC significantly increased its stake in Surgery Partners, Inc. by 3,229.1% in the fourth quarter, acquiring 549,945 additional shares. This brings their total holdings to 566,976 shares, valued at approximately $8.76 million. Other institutional investors also adjusted their positions, and the company authorized a $200 million stock buyback program, indicating management views the stock as potentially undervalued despite missing Q4 EPS consensus.
Vanguard disaggregates holdings; reports 0 shares in Surgery Partners (SGRY)
Vanguard Group has filed an amended Schedule 13G/A, indicating 0% ownership in Surgery Partners (SGRY) following an internal realignment on January 12, 2026. This realignment means certain Vanguard subsidiaries will now report their beneficial ownership separately, relying on SEC Release No. 34-39538. The filing, signed by Ashley Grim, Head of Global Fund Administration, states that Vanguard no longer beneficially owns the securities held by these disaggregated entities.
SGRY Price Today: Surgery Partners, Inc. Stock Price, Quote & Chart
This article provides an overview of Surgery Partners, Inc. (SGRY) stock, including its current trading price, market data, and recent performance. It details how to buy SGRY on MEXC and offers frequently asked questions about the company's financials, sector classification, and dividend policy. The stock is currently trading at $11.45, reflecting a weak performance over the past year.
SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED --
Levi & Korsinsky, LLP is investigating Surgery Partners (NASDAQ: SGRY) following a sharp stock drop in early March 2026. This comes after the company's Q4 2025 results and FY 2026 outlook missed expectations, despite earlier assurances from CEO Eric Evans concerning margin expansion and sustained double-digit earnings growth. The investigation seeks to determine if management was aware of mounting headwinds, such as payer-mix shifts and anesthesia-cost dynamics, when issuing optimistic forward guidance.
A Look At Surgery Partners (SGRY) Valuation After Recent Share Price Weakness
Surgery Partners (SGRY) has experienced recent share price weakness, with its stock closing at US$11.80 and showing significant declines over various periods. Despite this, the stock is considered 53.6% undervalued according to a popular narrative, with a fair value estimate of $25.45, suggesting a potential opportunity for investors. The valuation narrative relies on future earnings and cash flow improvements, driven by disciplined M&A and portfolio optimization.
A Look At Surgery Partners (SGRY) Valuation After Recent Share Price Weakness
Surgery Partners (SGRY) has experienced recent share price weakness, with the stock closing at US$11.80 and showing significant declines over the past month, three months, and year. Despite trading well below a narrative fair value of approximately $25.45, suggesting it is 53.6% undervalued, the valuation is heavily reliant on future earnings and cash flow improvements. Investors are encouraged to consider the full picture, including potential risks from rising interest costs or slower acquisitions, before making investment decisions.
SGRY SEC Filings - Surgery Partners Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Surgery Partners Inc. (SGRY) SEC filings, including 10-K, 10-Q, and 8-K reports, designed for investors to track the company's financial performance, governance, and material events. It details recent filings such as debt refinancings, insider stock transactions, and changes in beneficial ownership, with AI-powered summaries for quick insights. The platform aims to offer transparency into the healthcare services company's regulatory disclosures.
SGRY SEC Filings - Surgery Partners Inc 10-K, 10-Q, 8-K Forms
This page provides access to Surgery Partners Inc. (SGRY) SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed information on the company's business, finances, and material events. Recent Form 144 filings highlight significant insider stock sales by Wayne DeVeydt, totaling hundreds of thousands of shares, concurrently with equity compensation exercises, indicating planned disposals. Additionally, an 8-K filing reports the resignation of National Group President Harrison R. Bane, effective October 3, 2025, noting it is not due to company disagreements.
SGRY SEC Filings - Surgery Partners Inc 10-K, 10-Q, 8-K Forms
This article provides access to Surgery Partners Inc. (SGRY) SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed regulatory disclosures. It highlights the company's financial overview, business structure, and recent insider trading activities, such as Form 144 filings detailing share sales by executives like Wayne DeVeydt and Harrison R. Bane. The platform also utilizes AI-powered tools to summarize these lengthy filings for quick investor insights.
Hudson Bay Capital Management LP Sells 133,637 Shares of Surgery Partners, Inc. $SGRY
Hudson Bay Capital Management LP has reduced its stake in Surgery Partners, Inc. (NASDAQ:SGRY) by 28.2%, selling 133,637 shares and now owning 339,609 shares valued at $7.35 million. This comes as Surgery Partners announced a $200 million share buyback program and reported mixed financial results, with revenue beating estimates but earnings per share missing. The company currently holds a "Moderate Buy" rating from analysts with a consensus price target of $23.36.
Surgery Partners stock hits 52-week low at 12.22 USD By Investing.com
Surgery Partners Inc (SGRY) stock recently fell to a 52-week low of $12.22, marking a significant decline of 49.38% over the past year. Despite challenges including a negative insurance mix shift, analysts see potential for a 62% upside and expect profitability this year, with the stock appearing undervalued according to InvestingPro Fair Value analysis. Recent developments for the company include adjusted price targets from TD Cowen and RBC Capital, an activist investor campaign by Ortelius Advisors, and a new independent director appointment.
Surgery Partners Inc (SGRY) Trading Down 2.45% on Mar 18
Surgery Partners Inc (SGRY) shares dropped 2.45% on March 18, closing at $12.34. This places the stock significantly below its 52-week high but slightly above its 52-week low. Analysts have an average price target of $19.34, suggesting a 56.73% upside, while GuruFocus estimates a one-year fair value of $30.47, indicating a 146.92% upside.
Surgery Partners stock hits 52-week low at 12.22 USD
Surgery Partners (SGRY) stock has fallen to a 52-week low of $12.22, marking a 49.38% decline over the past year. Despite its high volatility and market challenges, analysts predict a potential 62% upside and future profitability, with some firms adjusting price targets while maintaining 'Buy' ratings. The company is undergoing strategic changes, including a new independent director appointment and a call for activist investor-led restructuring.
Surgery Partners or Tenet Healthcare: Which Stock Has More Upside?
This article analyzes whether Surgery Partners (SGRY) or Tenet Healthcare (THC) offers more upside for investors. It concludes that Surgery Partners is a better investment due to superior revenue growth, higher profitability, and a relatively lower valuation compared to Tenet Healthcare. The analysis includes a detailed comparison of financial metrics, historical market performance, and risk factors for both companies.
SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES
Levi & Korsinsky, LLP is investigating Surgery Partners (NASDAQ: SGRY) after its stock dropped sharply in March 2026 following Q4 2025 results and FY 2026 outlook that fell short of expectations. The investigation focuses on whether management's earlier guidance for margin expansion and significant growth concealed known cost pressures and operational risks. Shareholders who suffered losses are encouraged to contact the law firm to discuss their legal rights.
SGRY GUIDED FOR MARGIN EXPANSION WHILE HEADWINDS MOUNTED -- LEVI & KORSINSKY, LLP INVESTIGATES
Levi & Korsinsky, LLP is investigating Surgery Partners (NASDAQ: SGRY) after the company's Q4 2025 results and FY 2026 outlook fell short of expectations, causing a sharp stock drop in early March 2026. This investigation follows previous assurances from CEO Eric Evans and CFO Dave Doherty about expected margin expansion and sustained double-digit earnings growth, which did not materialize. Shareholders who incurred losses are encouraged to contact the law firm to discuss their legal rights, as it is suspected that management may have known about mounting cost pressures and operational risks when issuing previous positive guidance.
Surgery Partners (SGRY) CFO disposes shares to cover tax withholding
Surgery Partners, Inc.'s CFO, David T. Doherty, sold 8,867 shares of common stock at a weighted average price of $12.50 per share. This transaction was carried out to cover tax withholding obligations associated with the vesting of restricted stock on March 4, 2026. After the sale, Doherty still retains a substantial direct holding of 221,679 shares in the company.
Farallon Capital Management LLC Cuts Stock Position in Surgery Partners, Inc. $SGRY
Farallon Capital Management LLC significantly reduced its stake in Surgery Partners, Inc. by 54.7% in the third quarter of 2025, selling over 1 million shares. Insider selling by major executives was also noted, contributing to a total of 54,705 shares sold by insiders in the last 90 days. Despite the Q3 earnings per share missing analyst estimates, Surgery Partners announced a $200 million share buyback program and maintains a "Moderate Buy" consensus rating from analysts.
Insider Selling: Surgery Partners (NASDAQ:SGRY) Insider Sells 3,657 Shares of Stock
Marissa Brittenham, an insider at Surgery Partners (NASDAQ:SGRY), sold 3,657 shares of the company's stock for approximately $45,859, reducing her stake by 3.74%. This transaction follows a previous sale of 8,785 shares earlier in March. The company recently reported Q4 2025 earnings of $0.12 EPS, missing consensus, but beat revenue estimates with $885 million, up 2.4% year-over-year, and authorized a $200 million stock buyback program.
Surgery Partners (NASDAQ:SGRY) CEO Jason Eric Evans Sells 20,400 Shares
Surgery Partners (NASDAQ:SGRY) CEO Jason Eric Evans sold 20,400 shares of the company's stock on March 16th at an average price of $12.47. This transaction reduced his stake by 2.17% to 920,386 shares. The sale follows a previous transaction on March 6th and comes after the board authorized a $200 million share repurchase program, signaling a potential belief that the stock is undervalued despite mixed recent quarterly results.
Short Interest in Surgery Partners, Inc. (NASDAQ:SGRY) Decreases By 15.7%
Short interest in Surgery Partners, Inc. (SGRY) decreased by 15.7% to 13,812,095 shares as of February 27th, representing about 11.0% of the float and a 10.4 days-to-cover ratio. Analysts have a "Moderate Buy" consensus rating with an average target of $23.36, although some recent price target reductions have occurred. Insiders have sold shares, while the company authorized a $200 million share repurchase plan, indicating management believes the stock is undervalued.
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
Surgery Partners, Inc. announced the appointment of Lloyd Dean to its Board of Directors as an independent director. Mr. Dean brings extensive experience as the former CEO of CommonSpirit Health and Dignity Health, where he was recognized for advancing clinical quality, operational performance, and equitable access to care. His appointment is expected to provide invaluable insights as Surgery Partners continues to expand its high-quality, cost-effective surgical care offerings.
Activist investor calls for Surgery Partners leadership change By Investing.com
Activist investor Ortelius Advisors has sent an open letter to Surgery Partners, Inc. (NASDAQ:SGRY) stockholders, demanding significant leadership changes, including board refreshment and new management. Ortelius cited the company's substantial stock decline of 67% over five years, significantly underperforming market indices and peers. The firm proposed strategies such as divesting surgical hospitals to generate funds for stock repurchases and debt reduction, arguing that the remaining ambulatory surgery centers business would show stronger growth and higher EBITDA margins.
Surgery Partners (SGRY) Is Down 7.3% After Soft 2026 Outlook, Buyback Launch, and New Director
Surgery Partners (SGRY) shares fell 7.3% following its 2026 outlook, which included softer revenue guidance ($3.35B-$3.45B), despite reporting higher 2025 sales and launching a new $200 million share repurchase program. The company also appointed Lloyd Dean as an independent director while facing pressure from activist investor Ortelius Advisors. These developments intensify scrutiny on Surgery Partners' capital allocation, governance, and execution plans, especially given its ongoing net losses and significant debt.
Surgery Partners (SGRY) Is Down 7.3% After Soft 2026 Outlook, Buyback Launch, and New Director
Surgery Partners (SGRY) shares fell 7.3% after reporting 2025 results with higher sales but continued net losses and issuing softer 2026 revenue guidance. The company also announced a new $200 million share repurchase program and appointed a new independent director, Lloyd Dean. These developments intensify scrutiny on the company's capital allocation, governance, and execution, especially given activist investor pressure and a heavy debt load.
8 Knots Management LLC Takes Position in Surgery Partners, Inc. $SGRY
8 Knots Management LLC recently acquired 220,088 shares of Surgery Partners, Inc. (NASDAQ:SGRY) for approximately $4.76 million, making SGRY its 19th largest holding. This comes as Surgery Partners announced a $200 million share buyback program, despite missing Q3 earnings estimates with an EPS of $0.12 against an expected $0.31. The stock is currently trading near its 52-week low with a "Moderate Buy" consensus rating from analysts.
Ex-CommonSpirit CEO Lloyd Dean joins Surgery Partners board
Surgery Partners, Inc. (NASDAQ: SGRY) announced the appointment of Lloyd Dean, former CEO of CommonSpirit Health, to its Board of Directors as an independent director. Dean brings extensive experience in national healthcare leadership, having spearheaded the formation and integration of CommonSpirit Health and served as President and CEO of Dignity Health. His appointment is expected to support Surgery Partners' expansion in high-quality, cost-effective outpatient surgical care, leveraging his expertise in clinical quality, operational performance, and public health policy.
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
Surgery Partners, Inc. announced the appointment of Lloyd Dean, former CEO of CommonSpirit Health, to its Board of Directors as an independent director. Dean is a nationally recognized healthcare leader with extensive experience in health system management, public policy advising, and efforts to reduce health disparities. The company anticipates his expertise will be invaluable as it continues to expand its high-quality, cost-effective surgical care services nationwide.
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
Surgery Partners, Inc. (NASDAQ:SGRY) has appointed Lloyd Dean, former CEO of CommonSpirit Health, to its Board of Directors as an independent director. Dean is a nationally recognized healthcare leader with extensive experience in health system leadership, public policy, and efforts to reduce health disparities. The company anticipates his insights will be invaluable as they continue to expand high-quality, cost-effective surgical care.
Surgery Partners, Inc. Appoints Lloyd Dean as Independent Director to Board of Directors
Surgery Partners, Inc. has announced the appointment of Lloyd Dean, former CEO of CommonSpirit Health, as an independent director to its Board of Directors. Dean brings extensive experience in healthcare leadership, with a focus on clinical quality, community health, and reducing health disparities. This appointment is expected to provide invaluable insights for Surgery Partners' continued growth in high-quality outpatient surgical care.
Surgery Partners (SGRY) Is Down 9.7% After Soft 2026 Outlook And New Buyback Plan - Has The Bull Case Changed?
Surgery Partners (SGRY) reported Q4 and full-year 2025 results with increased sales but continued net losses, alongside a softer 2026 revenue guidance and a new $200 million share repurchase authorization. These developments, along with activist investor pressure and insider stock sales, raise questions about the company's ability to balance growth, debt reduction, and shareholder returns. Investors are closely watching how the company deploys the buyback given the weaker guidance and calls to monetize hospital assets.
Assessing Surgery Partners (SGRY) Valuation After Activist Pressure And Mixed Earnings Updates
Surgery Partners (SGRY) is under scrutiny after activist investor Ortelius Advisors demanded asset sales and leadership changes, following softer Q4 guidance, analyst revisions, and insider share sales. Despite a recent share price gain, SGRY has seen significant declines over the past year, prompting questions about its valuation. The company is currently estimated to be 47% undervalued with a fair value of $25.45, but rising interest costs and slower acquisition activity pose risks to this assessment.
Surgery Partners (SGRY) Guided for Margin Expansion While Headwinds Mounted -- Levi & Korsinsky, LLP Investigates
Levi & Korsinsky, LLP is investigating Surgery Partners (SGRY) following a sharp stock drop in early March 2026, after its Q4 2025 results and FY 2026 outlook missed expectations. The investigation focuses on whether company management, including CEO Eric Evans and CFO Dave Doherty, concealed known cost pressures and operational risks when providing earlier optimistic guidance for margin expansion and growth. Shareholders who suffered losses are encouraged to contact the firm.
UBS Maintains Buy on Surgery Partners (SGRY) on March 11, 2026
UBS reiterated its Buy rating for Surgery Partners (SGRY) on March 11, 2026, following an activist letter to shareholders. The firm maintained its investment thesis without issuing a new price target, suggesting continued operational upside. The market reaction was modest, with a 1.2% stock price increase, indicating investors absorbed the news calmly amidst ongoing activist pressure.
Surgery Partners at Barclays Healthcare Conference: Strategic Plans Amid Challenges
Surgery Partners (NASDAQ:SGRY) participated in the Barclays 28th Annual Global Healthcare Conference, discussing strategies to address revenue impacts from payer mix shifts and to optimize free cash flow. The company detailed plans for cost reductions, portfolio optimization through potential divestitures of larger hospitals, and a $200 million share repurchase program. Despite challenges like margin compression due to increased Medicare patients, Surgery Partners emphasized strengthening physician partnerships and maintaining a conservative outlook for 2026 while targeting $200 million for M&A.
Ortelius Capital Management recently proposed a series of strategic adjustments for Surgery Partners, Inc., including a comprehensive overhaul of the board structure, the introduction of a new management team, and a systematic evaluation of the company’s
Ortelius Capital Management has proposed significant strategic changes for Surgery Partners, Inc., focusing on a comprehensive overhaul of the board structure, introducing a new management team, and evaluating the company's development strategy. The goal of these proposals is to unlock the healthcare service platform's potential value by optimizing its governance and improving operational efficiency.
Ortelius Delivers Open Letter To Surgery Partners Stockholders
Ortelius has issued an open letter to the stockholders of Surgery Partners (SGRY). The article, provided by Refinitiv and Reuters, is a brief news update regarding this communication from Ortelius to the company's investors.
Activist urges Surgery Partners to sell hospitals and raise billions
Ortelius Advisors, an activist investor, has sent an open letter to Surgery Partners stockholders, expressing deep concern over the company's 67% stock price drop over the past five years. Ortelius proposes a series of actions to unlock shareholder value, including selling all surgical hospitals to generate billions, repurchasing shares, reducing debt, and making changes to the board and management team. The firm believes these measures will transform Surgery Partners into a pure-play ambulatory surgery centers business with stronger financial metrics.
Surgery Partners to Present at Barclays Healthcare Conference
Surgery Partners, Inc. will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, at 2:30 p.m. ET. The company will showcase its outpatient delivery model and growth strategy to investors. A live webcast and replay will be available on Surgery Partners' website.
Precision Trading with Surgery Partners Inc. (SGRY) Risk Zones
This article analyzes Surgery Partners Inc. (SGRY), highlighting weak sentiment across all horizons and suggesting a short bias. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal data and access to real-time AI-generated signals for informed trading decisions.
Surgery Partners, Inc. Stock Plummets to New 52-Week Low at $12.25
Surgery Partners, Inc. (NASDAQ: SGRY) has hit a new 52-week low of USD 12.25, with its stock declining 45.77% over the past year. The company faces significant financial challenges, including a net profit loss of USD 13.29 million and a high debt-to-equity ratio of 1.46. Despite a market capitalization of USD 2,010 million, Surgery Partners has reported negative results for three consecutive quarters, contrasting sharply with the S&P 500's 17.36% gain.
Outpatient & Specialty Care Stocks Q4 Highlights: Surgery Partners (NASDAQ:SGRY)
Surgery Partners (NASDAQ:SGRY) reported softer-than-expected Q4 results with revenues beating estimates but full-year guidance missing significantly, causing the stock to drop 15.9%. In contrast, competitor DaVita (NYSE:DVA) had a strong quarter, exceeding revenue and EPS expectations, leading to a 35.5% stock increase. The outpatient and specialty care industry faces both tailwinds from an aging population and medical advancements, and headwinds from reimbursement cuts and labor shortages.
Assessing Surgery Partners (SGRY) Valuation After Recent Share Price Weakness And Undervalued Narrative
This article analyzes Surgery Partners (SGRY) after recent share price weakness, noting a 44.7% undervalued narrative. Despite negative returns over 3 months and a year, the stock trades near US$14.08 against a fair value estimate of US$25.45, driven by expectations of increased complex surgical volumes, M&A, and portfolio optimization. Investors are encouraged to further investigate the company's fundamentals and potential upsides.
Surgery Partners Faces Weak Start with 21.85% Gap Down Amid Market Concerns
Surgery Partners, Inc. experienced a significant 21.85% gap down at market open, reflecting broader market challenges and a -12.34% one-day performance. The small-cap hospital industry player, with a market capitalization of USD 2,010 million and a P/E ratio of 30.00, exhibits mixed technical indicators and a moderate debt-to-equity ratio of 1.46.
Analyst Expectations For Surgery Partners's Future
Five analysts have rated Surgery Partners (NASDAQ: SGRY) in the past three months, with sentiment shifting. The average 12-month price target is $18.20, a 23.53% decrease from the previous average. While the company shows positive revenue growth, its net margin, ROE, and ROA lag behind industry averages, indicating challenges in profitability and asset utilization.
UBS Maintains 'Buy' Rating for Surgery Partners (SGRY), Lowers P
UBS has maintained its 'Buy' rating for Surgery Partners (SGRY) but lowered its price target from $29.00 to $21.00. This adjustment follows similar actions from other firms like RBC Capital and Barclays, which also reduced their price targets for SGRY. Despite the lowered targets, the average analyst target price still implies an upside of 44.43% from the current price, and GuruFocus estimates a potential upside of 135.98% based on its GF Value.
Surgery Partners (NASDAQ:SGRY) Price Target Cut to $17.00 by Analysts at Mizuho
Mizuho analysts lowered their price target on Surgery Partners (NASDAQ:SGRY) to $17.00 from $19.00 but maintained an "outperform" rating, indicating a potential upside of 20.74%. The company recently missed EPS estimates but beat revenue expectations, and its board approved a $200 million share buyback. Despite mixed analyst sentiment, the consensus remains a "Moderate Buy" with an average target price of $25.70.
Assessing Surgery Partners (SGRY) Valuation After Recent Share Price Weakness And Undervalued Narrative
Surgery Partners (SGRY) has experienced mixed trading, with recent negative returns but an uptick on the latest day, trading near US$14.08. Despite an ongoing net income loss, a narrative suggests the stock is undervalued with a fair value estimated around $25.45, based on expectations of increased surgical volumes and strategic execution. However, this upside could be challenged by rising interest costs or slower acquisitions.
